Gigantism refers to abnormally high linear growth due to excessive action of insulinlike growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the growth plate cartilage fuses in adulthood.
The global acromegaly and gigantism treatment market can be segmented into treatment, end users, and geographical expansion. On the basis of treatment, the market is divided into surgery, radiation therapy, and medication. The medication segment can be further divided into different drug types such as somatostatin analogs, GH receptor antagonists, dopamine agonists and others. The medication segment is expected to hold a significant market share during the forecast period due to factors such as effectiveness of drugs, noninvasive and lesser side effects than radiation therapies, and strong pipeline portfolio. 

The global Acromegaly and Gigantism Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Acromegaly and Gigantism Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Acromegaly and Gigantism Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Acromegaly and Gigantism Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Acromegaly and Gigantism Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Ipsen
Novartis
Pfizer
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Somatostatin Analogs
GH Receptor Antagonists
Dopamine Agonists
Recombinant Human IGF-1

Segment by Application
Hospitals
Clinics
Others